NanoViricides is a development-stage company engaged in creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates is designed for the specific purpose of attacking and dismantling enveloped virus particles. NanoViricides is developing drugs against various viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes (HSV), viral diseases of the eye, Ebola virus and others. For more information, visit the company’s Web site at www.nanoviricides.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: